Neurodegenerative disorders
Conditions
Interventions
None listed
Sponsors
Rijksuniversiteit Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients must be diagnosed with Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI) or Parkinson's disease (PD) by an experienced neurologist according to published criteria: 1. Patients with probable AD dementia according to the criteria of The National Institute on Aging and the Alzheimer*s Association (McKhann et al., 2011). 1a. Only patients in the early stages of the disease (i.e. within two years after diagnosis) will be included, since in the later stages of disease the understanding of test instructions might be questioned. 2. Patients with amnestic MCI (single and multi-domain) according to the criteria of The National Institute on Aging and the Alzheimer*s Association (Albert et al., 2011). 3. Patients with idiopathic PD according to the UK Parkinson*s Disease Society Brain Bank Criteria (Hughes, Daniel, Kilford, & Lees, 1992). 3a. Only patients in the early stages of the disease (i.e. within five years after diagnosis) will be included, since in the later stages of disease the understanding of test instructions might be questioned., In case of medication use, patients and healthy controls must be on a stable dosage of medication for at least one month.
Exclusion criteria
Exclusion criteria: 1. Presence of a neurological central nervous system disorders other than AD, MCI or PD. 2. Surgical treatment for idiopathic PD, such as deep brain stimulation. 3. Other significant co-morbidity which might have an influence on cognition: 3a. Cardiovascular diseases, including severe hypertension. 3b. Cardiovascular risk factors, such as diabetes. 3c. Clinically evident psychological / psychiatric disorders, such as depression, anxiety, apathy and fatigue.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary parameters of this study are the performances of patients with AD, MCI and PD on FDM tasks compared to healthy controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary parameters of this study are the performances of patients with AD, MCI and PD on standard neuropsychological tasks. | — |
Countries
Netherlands
Outcome results
None listed